#61
|
||||
|
||||
Öèòàòà:
|
#62
|
||||
|
||||
Åñëè á âñå áûëè íîðìàëüíûìè (âî âñåõ ïðîôåññèÿõ), òî æèëè áû ìû íå òàì ãäå æèâåì, à â ñêàçî÷íîì öàðñòâå-ãîñóäàðñòâå
|
#63
|
|||
|
|||
íó, ÷òî æå. ãîñïîäà, ïîçâîëþ ñåáå ÷óòü -÷óòü ïîçóáîñêàëèòü. Íàäåþñü, âñå óæå âûñêàçàëè ñâîè ìíåíèÿ î òîì, ÷òî "Íè îäèí íîðìàëüíûé ôèçèîòåðàïåâò ïðè òðàâìå ëîêòÿ òåïëî íå íàçíà÷àåò" è "Êòî-òî ðèñêíåò ïàðàôèíèòü è ìàññàæèðîâàòü ëîêòåâîé ñóñòàâ?"
Ïîæàëóéñòà - äâîéíîå, ñëåïîå, ðàíäîìèçèðîâàííîå, îôîðìëåííîå ïî âñåì ïðàâèëàì è òä [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Use of TPD Heat Lamp for Tennis Elbow Pain - a Randomized-Controlled Trial èëè èíôðàêðàñíàÿ ëàìïà - íå òåïëî? èëè tennis elbow - íå òðàâìà? Òàê ÷òî, Àñëàí, íå ñïåøèòå ðâàòü íà ñåáå îäåæäó, à ëó÷øå ïîäîæäèòå îêîí÷àíèÿ òðàÿëà - à âäðóã èçâèíÿòüñÿ ïåðåä òðàâìàòîëîãîì ïðèäåòñÿ |
#64
|
|||
|
|||
È åùå, îáðàòèòå âíèìàíèå âîò íà ýòó ôðàçó - The normal treatment for tennis elbow pain is oral pain relief medication (analgesia), and/or physiotherapy, local massage or even surgery
|
#65
|
||||
|
||||
Âî-ïåðâûõ, õî÷åòñÿ ñêàçàòü êîìïëèìåíò äîêòîðó Golosa çà óìåíèå ñïðîâîöèðîâàòü èíòåðåñíóþ äèñêóññèþ.
Ñåðãåé, â âûäåëåííîé Âàìè ôðàçå íå âèæó íè÷åãî íîâîãî. Ðîâíî òî æå, è äàæå áîëüå, íàïèñàíî â òîì å Campbell's OO: nonoperative treatment includes rest, ice, injections, and physical therapy with ultrasound, iontophoresis, electrical stimulation, manipulation, soft-tissue mobilization, friction massage, stretching and strengthening exercises, and counterforce bracing. È ÿ íå ñ÷èòàþ tennis elbow òðàâìîé, âñ¸-òàêè ýòî òåíäèíîïàòèÿ. Çäåñü íåò õàðàêòåðíûõ äëÿ òðàâìû êîíòóçèè ìÿãêèõ òêàíåé è àêòèâíûõ ðóáöîâõ ïðîöåññîâ. Îïÿòü æå ìàññàæ ðåêîìåíäóåòñÿ ëîêàëüíûé, à íå ñóñòàâà â öåëîì. Åñëè Âû èìåëè ââèäó, ÷òî èññëåäîâàíèÿ âîçäåéñòâèÿ òåïëîâûõ ïðîöåäóð íà ëîêòåâîé ñóñòàâ âîîáùå äåëàþòñÿ - ñîãëàøóñü. Íî...  ñòàòüå íàïèñàíî òîëüêî TDP Heat-lamp, íî íå îïèñàíû å¸ õàðàêòåðèñòèêè: êàêîé ðàçìåð ëàìï, êêîå ôîêóñíîå ðàññòîÿíèå, êàêîâà ïëîùàäü âîçäåéñòâèÿ. Íà ñêîëüêî ÿ ñìîã ïîíÿòü èç ñåòè, ëàìïû ýòè ðàçíûå è íåêîòîðûå èñïîëüçóþòñÿ êàê íå÷òî âðîäå àêóïóíêòóðû. _________________________________ Ñ óâàæåíèåì, Äìèòðèé Âëàäèìèðîâè÷ |
#66
|
||||
|
||||
Êàê ÿ ïîíÿë (ñ ìîèì ïëîõèì àíãëèéñêèì) òðàÿë íåâíÿòíûÉ íåìíîãî, íàïðàâëåí íà äîêàçàòåëüñòâî ïîëüçû çàïàòåíòîâàííîé êèòàéñêîé ëàìïû òîëüêî ïðè ëàòåðàëüíîì ýïèêîíäèëèòå. Ïðè ýòîì íå óêàçûâàåòñÿ òåìïåðàòóðà âîçäåéñòâèÿ è ñðàâíèâàòü ñ îòå÷åñòâåííûìè ñïîñîáàìè ïðîãðåâàíèÿ òðóäíî. Âîçäåéñòâèå íà îáë. íàäìûùåëêà, à ýòî íå ñîâñåì ñóñòàâ. È ïðè ýòîì â èññëåäîâàíèå êàê ðàç íå âîøëè áîëüíûå ñ ïåðåëîìàìè íàäìûùåëêîâ èëè ëîêòåâîãî ñóñòàâà.À ýïèêîíäèëèò- äåéñòâèòåëüíî íå òðàâìà.
Ï.ñ.:îäåæäó ðâàòü íå áóäó, ÿ íà íåå ñ òðóäîì çàðàáàòûâàþ |
#67
|
|||
|
|||
|
#68
|
|||
|
|||
Öèòàòà:
|
#69
|
|||
|
|||
Öèòàòà:
To systematically review the beneficial and harmful effects of the prophylactic administration of corticosteroids, compared with placebo, in pediatric open heart surgery.” - Robertson-Malt S, Afrane B, El Barbary M. Prophylactic steroids for pediatric open heart surgery. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD005550. DOI: 10.1002/14651858.CD005550.pub2. Ñêàæó ãðóáî íàñ÷åò ýòèêè (ñîçíàþ, ñåé÷àñ ñàì âçîðâó ñèòóàöèþ) – àòîìíóþ áîìáó ñáðîñèëè â ñâîå âðåìÿ, ÷òîáû êîå-÷òî ïðîâåðèòü. Ñîãëàñåí, äàâíî ýòî áûëî, íî êàêàÿ-òî ýòèêà òîæå â òî âðåìÿ ñóùåñòâîâàëà. Ìîæíî ïðèâåñòè è ìíîæåñòâî ñîâðåìåííûõ ïðèìåðîâ. Íà Çàïàäå äëÿ òàêèõ «ýêñïåðèìåíòîâ» îôèöèàëüíî äàæå ñóùåñòâóþò õîðîøî îïëà÷èâàåìûå âîëîíòåðû. À íåîôèöèàëüíî è ó íèõ, è ó íàñ – íå áóäó ðàññòðàèâàòüñÿ.  ïîãîíå çà ïðèáûëüþ ìîæíî äàæå î÷åíü «ýòè÷íî» ïðèäóìàòü êàêóþ-òî áîëåçíü è ñðàçó ê íåé è ïðîòèâîÿäèå, ïðè÷åì ïðîâåðèâ åãî äåéñòâåííîñòü íà íàñåëåíèè èç «íåäîðàçâèòûõ ñòðàí». Òàê ãäå òàì «ýòè÷íûå» êîìèòåòû – ó íèõ è , òåì áîëåå, ó íàñ? À ðàçâå íåèçâåñòåí òàêîé èíòåðåñíûé òåðìèí «ëîááè»? À î êàêîé ýòèêå ìîæíî ãîâîðèòü, åñëè èññëåäîâàòåëè ïðè ïëàíèðîâàíèè èññëåäîâàíèÿ-ýêñïåðèìåíòà íàä ëþäüìè óæå çàðàíåå çíàþò î âðåäíîñòÿõ-âûðàæåííûõ îïàñíûõ ïîáî÷íûõ äåéñòâèÿõ ëåêàðñòâ? È çíàÿ âñå ýòî, íàçíà÷àþò ýòè ëåêàðñòâà áîëüíûì, ñðàâíèâàÿ, êàêîå ëåêàðñòâî áîëåå âðåäíîå. LAIRE BOMBARDIER, LOREN LAINE, ALISE REICIN. COMPARISON OF UPPER GASTROINTESTINAL TOXICITY OF ROFECOXIB AND NAPROXEN IN PATIENTS WITH RHEUMATOID ARTHRITIS. - The New England Journal of Medicine(N Engl J Med 2000;343:1520-8.) - «It has been estimated that more than 100,000 patients are hospitalized and 16,500 die each year in the United States as a result of NSAID-associated gastrointestinal events. The primary hypothesis was that the risk of confirmed upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers) would be lower among patients who were taking rofecoxib than among those who were taking naproxen. Secondary hypotheses were that the risk of confirmed complicated events (perforation, obstruction, and severe upper gastrointestinal bleeding) and the risk of both confirmed and unconfirmed upper gastrointestinal events would be lower among patients who were taking rofecoxib.” Çíà÷èò âñå-òàêè åñòü òàêèå ðàáîòû? Ñàìè ïðèçíàåòå? À íàñ÷åò äèçàéíà çäåñü ðå÷è ïîêà íå øëî. Ðå÷ü øëà î âîîáùå – äîêàçûâàåòñÿ íàó÷íî âðåäîíîñíîñòü âîçäåéñòâèÿ èëè íåò. À ïî÷åìó ìåíÿ èíòåðåñóåò âðåä âîçäåéñòâèÿ, ÿ óæå ðàññêàçàë. Äóìàþ è äðóãèõ áîëåå èëè ìåíåå îòâåòñòâåííûõ âðà÷åé äîëæíî ýòî èíòåðåñîâàòü, ó÷èòûâàÿ ãëàâíûé ïðèíöèï ìåäèöèíû. |
#70
|
|||
|
|||
Öèòàòà:
Òàê, äîïóñòèì, ÿ – âåëèêèé èññëåäîâàòåëü. Ìíå íå íðàâèòñÿ ïðåïàðàò êîíêóðåíòà ( ñàì âèäåë ó ñâîèõ áîëüíûõ, ÷òî äàåò áîëüøîå êîëè÷åñòâî îñëîæíåíèé, òî åñòü ïî ìîåìó ìíåíèþ – ïðåïàðàò «âðåäíûé», õîòÿ êîíêóðåíò çàÿâëÿåò îáðàòíîå), à ïðåïàðàò ìîåé ôèðìû-ñïîíñîðà – äåéñòâèòåëüíî, ãîðàçäî ëó÷øèé. Ñîçíàòåëüíî ( âåäü ÿ çíàþ î âðåäíîñòè ïðåïàðàòà êîíêóðåíòà) ëå÷ó îäíó ýêñï. è êîíòð. ãðóïïû «âðåäíûì» ïðåïàðàòîì êîíêóðåíòà, è òàêèå æå ãðóïïû ëå÷ó ñâîèì «ïîëåçíûì». Òàêèå æå èññëåäîâàíèÿ ïðîâîäÿòñÿ â äðóãèõ öåíòðàõ, êîòîðûå ïîëó÷èëè äåíüãè íà ýòî èññëåäîâàíèå, äîïóñòèì èç äðóãèõ êàêèõ-òî èñòî÷íèêîâ, à íå îò ôèðìû-ñïîíñîðà-ïðîèçâîäèòåëÿ. Íî ìîå ëè÷íîå èññëåäîâàíèå îñòàåòñÿ « çà êàäðîì» - ÿ æå çàèíòåðåñîâàííîå ëèöî-ðàçðàáîò÷èê ïðîåêòà.  êîíöå áîëüøîãî ìóëüòèöåíòðîâîãî èññëåäîâàíèÿ ïîëó÷àþòñÿ îæèäàåìûå ðåçóëüòàòû ( ÿ, êàê è ôèðìà-ñïîíñîð-ïðîèçâîäèòåëü, âåäü îæèäàë, ÷òî ïðåïàðàò êîíêóðåíòà ïðèíîñèò â áîëüøèíñòâå ñâîåì íå ïîëüçó, à âðåä) – ïðåïàðàò âðåäèò áîëüíîìó. ß äîêàçàë ñâîå ïðåäïîëîæåíèå, ïîýòîìó èç-çà «âðåäíîñòè» ïðåïàðàò êîíêóðåíòà ñíÿò ñ ïðîèçâîäñòâà. Ïëîõî ëè, íåýòè÷íî ÿ ïîñòóïèë, äîêàçàâ âðåä, êîòîðûé íàíåñ ïðåïàðàò ìíîæåñòâó ëþäåé? À âåäü íåäîáðîñîâåñòíàÿ ôèðìà-ïðîèçâîäèòåëü çàðàáîòàëà íà ãîðå ëþäåé ìàññó äåíåã. ×òî, íå áûâàåò òàêîãî â æèçíè? Âñå ÷åñòíî, áåñêîðûñòíî è áëàãîíàìåðåííî íàó÷íî äîêàçûâàþò ïîëåçíîñòü âîçäåéñòâèÿ-ïðåïàðàòà-èìïëàíòàòà? ß áû íå îñòàíîâèëñÿ íà ïîë-äîðîãè, à äîáèë áû äî êîíöà êîíêóðåíòà è íà÷àòîå äåëî. È ìíå õîðîøî ( ïîëó÷ó ïðè÷èòàþùèåñÿ äåíåæêè îò ôèðìû) è ëþäåé ñïàñó îò âðåäíîãî âîçäåéñòâèÿ ïðåïàðàòà, êîòîðûé âûïóñêàëà íåäîáðîñîâåñòíàÿ ôèðìà. Òàê ÷òî è äîêàçàòåëüñòâà âðåäà èìåþò î÷åíü ìíîãî ïîëîæèòåëüíûõ ìîìåíòîâ. Ìîæåò áûòü ÿ è íå ïðàâ. Õîòÿ, êòî åãî çíàåò. Äà, âîò èìåííî ïî òàêîìó ïðèíöèïó è ïîñòóïèëî FDA, èçúÿâ èç îáðàùåíèÿ «âðåäíûé» ïðåïàðàò, ïðè÷åì íàó÷íî äîêàçàâ åãî ÂÐÅÄ- «In April 2005, an FDA advisory committee concluded that valdecoxib was associated with an increased rate of serious and potentially life-threatening skin reactions (toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme) compared to other COX-2-selective NSAIDs, and the committee recommended withdrawing valdecoxib». - American Journal of Health-System Pharmacy, Vol. 63, Issue 19, 1837-1851 |
#71
|
|||
|
|||
Öèòàòà:
À âîò ÿ, êàê ïðàêòè÷åñêèé âðà÷, óâèäåë âäðóã, ÷òî òåïëî ïîìîãàåò ïðè ðàçëè÷íûõ ñèòóàöèÿõ, â ÷àñòíîñòè ïðè ïðîáëåìàõ ñ äðóãèìè ñóñòàâàìè. À ïî÷åìó áû ìíå íå ïîïðîáîâàòü èñïîëüçîâàòü åãî-òåïëî íà ëîêòåâîì ñóñòàâå? Íî âåäü ñòðåìíî, òàê êàê çíàþ, ÷òî ëîêòåâîé ñóñòàâ íå íàäî ìàññàæèðîâàòü è ãðåòü ( â øêîëå ó÷èòåëÿ ó÷èëè). Ñàì íå ïðîâåðÿë – îïÿòü æå ñòðåìíî. Íà÷èíàþ èñêàòü ëèòåðàòóðó – äåéñòâèòåëüíî ëè òàê âðåäíî? È âäðóã íè÷åãî î âðåäîíîñíîñòè íå íàõîæó. Òàê ÷òî, ìîæíî èëè íåëüçÿ? Èìåþ ÿ ïðàâî, êàê ïðàêòè÷åñêèé âðà÷, çàäàòü ñåáå òàêèå âîïðîñû è ïîñòðîèòü òàêóþ ëîãè÷åñêóþ öåïî÷êó? Òàê âîò åñëè, â êîíöå êîíöîâ, î âðåäå íè÷åãî íå íàïèñàíî, à î ïîëîæèòåëüíîì âëèÿíèè òåïëà íà äðóãèå ñóñòàâû ÿ çíàþ, òî ÿ âïîëíå ìîãó èñïîëüçîâàòü òåïëî è íà ëîêòåâîé ñóñòàâ, ïðè÷åì «íå íàâðåäèâ» áîëüíîìó – ñîáëþäàþ îñíîâíîé ïðèíöèï ìåäèöèíû. Ïî÷åìó ìíå, ïðàêòè÷åñêîìó âðà÷ó âäðóã çàïðåùåíî ïðîÿâèòü ïîëåçíóþ èíèöèàòèâó, òåì áîëåå, ÷òî âðåäà ÿ íå íàíåñó? Òàêàÿ èíèöèàòèâà äîëæíà òîëüêî ïîääåðæèâàòüñÿ, à íå óáèâàòüñÿ íà êîðíþ. Èëèçàðîâ, êàæåòñÿ, òîæå íå áûë íàó÷íûì ðàáîòíèêîì, êîãäà ïðèäóìûâàë àïïàðàòû è ìåòîäèêè. Âîò ïîýòîìó ìåíÿ è èíòåðåñóþò ðàáîòû î âðåäå òîãî èëè èíîãî âîçäåéñòâèÿ. Ïîýòîìó íå íàäî ìåíÿ îãðàíè÷èâàòü â ìîèõ ïîèñêàõ ýòîãî ñàìîãî âðåäà – âðåäíûå ìàíèïóëÿöèè îïàñíû äëÿ äèïëîìà âðà÷à. Íàäåþñü îáúÿñíÿòü íåò íåîáõîäèìîñòè, çà÷åì ïðè íàçíà÷åíèè ËÞÁÎÃÎ ëå÷åíèÿ âðà÷ äîëæåí, êàê è áîëüíîé, çíàòü âñå ðèñêè-îñëîæíåíèÿ-ïîáî÷íûå äåéñòâèÿ ëåêàðñòâ-ëå÷åíèÿ. Ðåøèòü âîïðîñ ãðàìîòíî ïî-äðóãîìó íåâîçìîæíî. Èëè ó Âàñ â Åêàòåðèíáóðãå êàê-òî èíà÷å âñå ðåøàåòñÿ? Ïîó÷èòå. È âîîáùå-òî, ÿ óæå ãîâîðèë Âàì, ïðèâîäèë ïî ýòîìó ïîâîäó ðàáîòû, ÷òî äîêàçûâàåòñÿ íå òîëüêî ÏÎËÅÇÍÎÑÒÜ, à è ÁÅÑÏÎËÅÇÍÎÑÒÜ è ÂÐÅÄ. “There is clearly a danger that information from trials which have positive findings will become available sooner and therefore influence practice sooner than information from trials which show little or no benefit or, indeed, which may show HARM”. - Hopewell S, Clarke M, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No.: MR000011. DOI: 10.1002/14651858.MR000011.pub2. Çíà÷èò âñå-òàêè åñòü òàêèå ðàáîòû, êîòîðûå äîêàçûâàþò HARM ëåêàðñòâà, âîçäåéñòâèÿ, ñòðàòåãèè ëå÷åíèÿ è ò.ä ? Äàëüøå. “To quantify the potential HARM of beta blockers on maximum walking distance, claudication distance, calf blood flow, calf vascular resistance, and skin temperature when used in patients with peripheral arterial disease (PAD)” - Paravastu SCV, Mendonca D, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD005508. DOI: 10.1002/14651858.CD005508.pub2.. «Authors' conclusions. Heavy sedation compared to light sedation does not confer additional benefits in terms of less severe withdrawal or increased rates of commencement on naltrexone maintenance treatment. Given that the adverse events are potentially life-threatening, the value of antagonist-induced withdrawal under heavy sedation or anaesthesia is not supported. The high cost of anaesthesia-based approaches, both in monetary terms and use of scarce intensive care resources, suggest that this form of treatment should NOT be pursued». - Gowing L, Ali R, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD002022. DOI: 10.1002/14651858.CD002022.pub2. «Authors' conclusions There is insufficient evidence to justify the use of corticosteroids in managing dengue shock syndrome. As corticosteroids can potentially do harm, clinicians should NOT use them unless they are participating in a randomized controlled trial comparing corticosteroids with placebo». - Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003488. DOI: 10.1002/14651858.CD003488.pub2. «Authors' conclusions The current available evidence primarily supports a lack of benefit of STI before switching therapy in patients with unsuppressed HIV viremia despite ART. There is evidence of harm in attempting STI in patients with relatively advanced HIV disease, due to the associated CD4 cell decline and the increased risk of clinical disease progression. At this time, there is no evidence to recommend the use of STI in this clinical category of patients with treatment FAILURE ». -Pai NP, Lawrence J, Reingold AL, Tulsky JP. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006148. DOI: 10.1002/14651858.CD006148 À ðàçâå Âàì íåèçâåñòíû ìíîãî÷èñëåííûå ðàáîòû, â êîòîðûõ èçëàãàþòñÿ ïîáî÷íûå (adverse) ýôôåêòû ëåêàðñòâ, ÷òî ñàìî ïî ñåáå è ÿâëÿåòñÿ âðåäîì? À äàæå åñëè âäðóã EBM ðàññìàòðèâàåò òîëüêî ëèøü ÏÎËÜÇÓ ïðåïàðàòà è óìàë÷èâàåò î åãî âðåäå – ýòî õîðîøî, ÷åñòíî, îòâåòñòâåííî? Ýòî åùå îäèí êàìåíü â îãîðîä êðèòèêè EBM – íå ëþáÿò èç-çà ýòîãî EBM-ùèêîâ ôàðìàêîýïèäåìèîëîãè. Ïî÷èòàéòå ñòàòüþ Luis Gabriel Cuervo: Editorial: Balancing benefits and harms in health care. We need to get better evidence about harms. - BMJ 2003;327:65-66 (12 July), doi:10.1136/bmj.327.7406.65 Öèòàòà:
|
#72
|
|||
|
|||
Öèòàòà:
Âñÿêî áûâàåò. Íàïðèìåð, íåò áàáîê íà èññëåäîâàíèå, äîêàçûâàþùåå ïîëåçíîñòü ÷åãî-òî, íåò ïîääåðæêè ñî ñòîðîíû îêðóæàþùåé ïóáëèêè ( êîãî-òî òàì äàæå ñîæãëè íà êîñòðå â ñâîå âðåìÿ- âåäü ðåøèë îïðîâåðãíóòü ÿðêèé, íåïîñðåäñòâåííûé è ñàìîî÷åâèäíûé äëÿ âñåõ ôàêò – Ñîëíöå âðàùàåòñÿ âîêðóã Çåìëè ) è ò.ä. À âîò ïðåäëîæåíèå ìîæåò áûòü, äåéñòâèòåëüíî, äåëüíûì. Òàê ÷òî – âñåãäà îáúåêòèâíî íåïðàâ? |
#73
|
|||
|
|||
Öèòàòà:
“Superficial moist heat and cryotherapy can be used as palliative therapy. Paraffin wax baths combined with exercises CAN be recommended for beneficial short-term effects for arthritic hands.” Îêàçûâàåòñÿ ïàðàôèí ïîëüçó ïðèíîñèò. À íàñ÷åò òîãî, ÷åì ãðåòü ëîêòåâîé ñóñòàâ – ïàðàôèíîì èëè ëàìïîé – âñå ðàâíî, ÷åì äîñòàâëÿòü òåïëî. Êîãäà íàñ ïðåäóïðåæäàëè î âðåäå òåïëà äëÿ ëîêòåâîãî ñóñòàâà, òî íèêòî íà ýòîì íå àêöåíòèðîâàë âíèìàíèÿ. Îáùèé âûâîä áûë – âðåäíî è îïàñíî. Êñòàòè, à òðàâìàòîëîã Ïàøà-Êîëÿøà -ßøà íè÷åãî äîìîé íå ïðèíîñèò, íàçíà÷àÿ ÁÀÄû, êàëüöèé â ñëîíèêàõ, àáñîëþòíî ëèøíèå è äîðîãîñòîÿùèå ëåêàðñòâà è èññëåäîâàíèÿ, äåëàÿ íåíóæíûå îïåðàöèè ñ èñïîëüçîâàíèåì äîðîãîñòîÿùèõ èìïëàíòàòîâ, êîòîðûå ïðîèçâîäÿò òîëüêî îïðåäåëåííûå ôèðìû, è îïðàâäûâàÿ ýòî óëó÷øåíèåì êà÷åñòâà æèçíè áîëüíîãî è ò.ä.? Âñå îäèíàêîâûå. Íå ñî÷òèòå ýòî íàïàäêàìè íà âðà÷åé-ó÷àñòíèêîâ Ôîðóìà – ÿ òîæå âðà÷. Ïðîñòî êîíñòàòèðóþ ôàêò. Íå íàäî ïîäíèìàòü îáèäíûå äëÿ äðóãèõ ìåäðàáîòíèêîâ òåìû. |
#74
|
|||
|
|||
Öèòàòà:
ß ïðîñèë ïðåäñòàâèòü öèòàòó èç _ýòîãî_ îáñóæäåíèÿ. È çàäàë âîïðîñ, êàêîå îòíîøåíèå ê èäóùåé äèñêóññèè èìååò âðåä òåïëà? Íè òîãî, íè äðóãîãî îïÿòü íåò. Íàïîìíþ, ÷òî ðàçãîâîð øåë î ïðåäïîëîæèòåëüíîé ïîëüçå íåêèõ ìåäèêàìåíòîâ ïðè íåéðîïàòèè. Ñ êàêîãî ïåðåïóãó âäðóã "êñòàòè" áûëî ïðèïëåòàòü âðåä òåïëà äëÿ ëîêòåâîãî ñóñòàâà? Ìàëî ëè êàêèå êòî â ðàçíîå âðåìÿ â äðóãèõ îáñóæäåíèÿõ ñäåëàë óòâåðæäåíèÿ íà âñÿêèå äðóãèå òåìû. Ýòîò ñàìûé âðåä òåïëà äëÿ ëîêòÿ (?) íèêàêîãî îòíîøåíèÿ íå èìåë ê îáñóæäàâøåìóñÿ âîïðîñó. Òàê ÷òî ïðèòÿãèâàíèå çà óøè ýòîãî âîïðîñà â äèñêóññèþ íà äðóãóþ òåìó áûëî ÷èñòûì òðîëëëèçìîì. Öèòàòà:
È "ñîãëàñîâàííîå ìíåíèå ýêñïåðòîâ" òóò èçáûòî÷íî, äîñòàòî÷íî îòñóòñòâèÿ óáåäèòåëüíûõ äîêàçàòåëüñòâ ïîëüçû. |
#75
|
|||
|
|||
Öèòàòà:
 îáùåì. ìîé âîïðîñ áûë ðèòîðè÷åñêèì. È íåò ëå÷åáíûõ âîçäåéñòâèé, äëÿ êîòîðûõ äîêàçûâàåòñÿ òîëüêî âðåä èëè äàæå åãî îòñóòñòâèå, à âîïðîñîì î ïîëüçå êàê-òî íèêòî íå îçàáî÷èâàåòñÿ. Öèòàòà:
Êàêèå - "òàêèå"? Ðàáîòû î âðåäå ëå÷åáíîãî âîçäåéñòâèÿ ïðè îòñóòñòâèè ðàáîò ñ äîêàçàòåëüñòâàìè åãî ïîëüçû? |